Acquisition of Enzalutamide

This tender concerns the procurement of Enzalutamide, a medication primarily used in the treatment of prostate cancer. The objective is to secure a supply of this pharmaceutical product, likely for a healthcare institution, hospital pharmacy, or public health program. Enzalutamide is a critical drug for patients diagnosed with specific forms of prostate cancer, including castration-resistant prostate cancer. The tender process aims to identify a reliable supplier capable of providing the medication in the required quantities, dosage forms, and packaging, while adhering to all relevant pharmaceutical regulations and quality standards. Bidders are expected to submit proposals that include details on the origin of the drug, manufacturing compliance (e.g., GMP certification), expiry dates, pricing, and delivery logistics. Ensuring an uninterrupted supply of essential medications like Enzalutamide is paramount for patient treatment and care. This procurement is vital for supporting oncology services and providing effective treatment options for prostate cancer patients.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 67,748.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.